TITLE

Insulin Treatment of Fasting or Postprandial Glucose in Type 2 Diabetes. Does It Matter? The South Danish Diabetes Study (SDDS)

AUTHOR(S)
Henriksen, Jan Erik; Gram, Jeppe; Beck-Nielsen, Henning
PUB. DATE
June 2007
SOURCE
Diabetes;Jun2007 Supplement 1, Vol. 56, pA51
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Insulin treatment of fasting hyperglycaemia using bedtime NPH insulin is often used in Type 2 diabetes whereas treatment of postprandial hyperglycaemia has not gained much impact. This investigator driven, randomised, intention to treat (ITT), and treat to target study compared the effect of NHP insulin given at bedtime with insulin Aspart alone given before the 3 main meals during 2 yrs. Beside insulin all patients received double blinded treatment with placebo or metformin or rosiglitazone or both, giving a total of 8 subgroups (factorial design). Patients treated with NPH insulin adjusted insulin dose based on measured fasting glucose concentrations and patients treated with Aspart based on glucose measured 1 1/2 hours following the meals. In total 371 patients with type 2 diabetes for at least 2 years and not sufficiently controlled on oral antidiabetic treatment and/or insulin were included. Age 56.3 ± 8.4yr (mean ± SD), BMI 33.9 ± 5.7 kg/m2, baseline HbA1c 8.6 ± 1.2%. 311 patients completed the study but data analysis is based on 369 ITT subjects. Overall, following 2 years treatment, Hba1c was significantly lower in patients treated with Aspart as compared to NPH insulin (-0,41%, (-0.6 to -0.22, 95% CI), p<0.001). Moreover, metformin treatment was associated with a decrease in Hba1c as compared to placebo (-0.60%, (-0.79 to -0.41), p<0.001) as was rosiglitazone (-0.55%, (-0.74 to -0.36), p<0.001). In subgroup analysis after 2 years treatment HbA1c was 8.3±1.3% in the NPH alone group, 7.8±1.1% in the Aspart alone group and in the two triple therapy groups treated with either Aspart or NPH insulin together with both metformin and rosiglitazone 7.0±1.0 and 6.8±0.9% respectively. Body weight increased more using insulin Aspart than using NPH insulin (5.9 ± 6.1 vs 4.7 ± 5.7 kg, p<0.01) whereas metformin versus placebo was associated with a lower increase (4.1 ± 5.5 vs 6.6 ± 6.0 kg, p<0.001) and rosiglitazone versus placebo with a greater increase (6.6 ± 6.4 vs 4.1 ± 5.1 kg, p<0.001). Clinical congestive hearth failure did not occur more often in patients treated with rosiglitazone. In conclusion treatment with insulin Aspart alone at mealtime is associated with a lower HbA1c as compared to treatment with NHP insulin at bedtime. Further addition of metformin and/or rosiglitazone to insulin treatment decreases HbA1c by approximately 0.6% each. Optimal treatment of Type 2 diabetes patients is best obtained by triple therapy combining insulin with metformin and rosiglitazone.
ACCESSION #
25820512

 

Related Articles

  • 10. Glucose control: Insulin-based therapies.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Jun2012, Vol. 17 Issue 2, pS32 

    The article discusses the use of insulin in treating patients with type 2 diabetes. It cites several studies that provide guidance for the rational use of various insulins in diabetes treatment, and offers recommendations for the initiation of basal insulin and pre-mixed insulin in diabetic...

  • Administration of Miglitol Until 30 Minutes After the Start of a Meal Is Effective in Type 2 Diabetic Patients. Terauchi, Yasuo; Aoki, Kazutaka; Nakamura, Akinobu; Nezu, Uru; Iwasaki, Tomoyuki; Takahashi, Mayumi; Kimura, Mari // Diabetes;Jun2007 Supplement 1, Vol. 56, pA562 

    Pharmacological agents are now available that primarily modify post-prandial plasma glucose levels. The alpha-glucosidase inhibitors (αGIs) represent one such class of agents whose intake is recommended just before a meal; however, adherence to these drugs has been reported to be lower than...

  • Short Insulin Tolerance Test May Determine Thiazolidinediones Treatment in Type 2 Diabetes. Lee, Mi Y.; Koh, Jang H.; Jung, Pil M.; Shim, Myoung S.; Kim, Mi J.; Shin, Jang Y.; Shin, Young G.; Chung, Choon H. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA578 

    The short insulin tolerance test is a simple and reliable method of estimating insulin sensitivity. This study was designed to compare the insulin sensitizing effects of thiazolidinediones (TZDs) on the degree of insulin resistance determined by short insulin tolerance test, Kitt in type 2...

  • Treatment of type 2 diabetes. Nazarko, Linda // British Journal of Healthcare Assistants;Mar2010, Vol. 4 Issue 3, p124 

    When a person has been diagnosed with type 2 diabetes, treatment aims to maintain normoglycaemia (blood sugar within normal limits), relieve the symptoms of diabetes, maintain or improve quality of life and prevent the complications associated with diabetes, such as stroke, heart attack, eye and...

  • Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. RIDDLE, MATTHEW C.; FORST, THOMAS; ARONSON, RONNIE; SAUQUE-REYNA, LEOBARDO; SOUHAMI, ELISABETH; SILVESTRE, LOUISE; LIN PING; ROSENSTOCK, JULIO // Diabetes Care;Sep2013, Vol. 36 Issue 9, p2497 

    OBJECTIVE--When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when glycated hemoglobin (HbA1c) remains elevated because of postprandial hyperglycemia, the next therapeutic step is controversial. We examined the efficacy and safety of...

  • Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats. Mori, A.; Lee, P.; Yamashita, T.; Nishimaki, Y.; Oda, H.; Saeki, K.; Miki, Y.; Mizutani, H.; Ishioka, K.; Honjo, T.; Arai, T.; Sako, T. // Veterinary Research Communications;Dec2009, Vol. 33 Issue 8, p957 

    Glimepiride and nateglinide are two common oral hypoglycemic agents currently being used with humans suffering from Type 2 diabetes mellitus. Neither drug has been tested with cats thus far and it is currently unknown whether either of these drugs exert any effect in cats or not. The objective...

  • Administrative Claims Analysis of New Exenatide Patients with Type 2 Diabetes. Wade, Ron; Quimbo, Ralph; Barron, John; Schroeder, Brock; Wintle, Matthew; Misurski, Derek; Oglesby, Alan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA561 

    Traditional antidiabetic therapies often fail to maintain glycemic control over time. In this retrospective analysis using a large, national commercial health care claims database, we describe baseline characteristics, comorbidities, and concomitant therapies in patients prescribed exenatide in...

  • Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Dailey, George; Rosenstock, Julio; Moses, Robert G.; Ways, Kirk // Diabetes Care;Oct2004, Vol. 27 Issue 10, p2363 

    Objective: Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. This study compared the safety and efficacy of glulisine with regular human insulin (RHI) in combination with NPH insulin.Research Design and Methods: In total,...

  • Approaches to Treatment of Type 2 Diabetes. Bloomgarden, Zachary T. // Diabetes Care;Aug2008, Vol. 31 Issue 8, p1697 

    Information about several papers discussed at the 55th Annual Advanced Postgraduate Course of the American Diabetes Society on treatment of type 2 diabetes held in San Francisco, California on February 1-3, 2008 is presented. Member Ralph DeFronzo said that glimepiride and glipizide reduced...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics